Japan has one of the most developed regulatory frameworks for regenerative medicine in the world. It has approved more cell therapies than almost any other country. It introduced a conditional approval pathway in 2013 specifically designed to get promising treatments to patients faster. Earlier this month, The Japan Times reported that a series of patients have died from regenerative treatments offered by private clinics operating outside that framework entirely. The question this raises is not unique to Japan.
THE RADAR
The first MSC therapy to clear full FDA scrutiny - and what it took
In December 2024, the FDA approved Ryoncil, developed by Mesoblast, as the first mesenchymal stem cell therapy ever to receive full approval in the United States. The indication is narrow: paediatric steroid-refractory acute graft-versus-host disease, a life-threatening immune complication that can follow bone marrow transplantation. The approval followed two previous rejections, years of iterative clinical work, and a Phase 3 trial published in Blood. This is the standard that full MSC approval requires, and almost nothing being sold in private clinics today has been through anything close to it.
Japan's regulatory review is now underway
In March, before the deaths received wider international attention, the Japanese Society for Regenerative Medicine held a press conference in Kobe calling for tighter oversight of uninsured regenerative treatments. The Japan Times covered the broader pattern of fatalities and violations the following month. Japan's response to this moment matters beyond its own borders, it pioneered the conditional approval model that other countries have since studied and in some cases adopted. What it does next will be watched.
What happens when the regulatory floor disappears
Japan built its regenerative medicine framework with genuine ambition. After years of watching promising cell therapies move slowly through conventional drug approval processes, the government introduced the Act on the Safety of Regenerative Medicine in 2013 and revised the Pharmaceutical and Medical Devices Act simultaneously. The intent was to create a faster, more flexible pathway - one suited to living cell therapies that do not behave like conventional drugs. Other countries took notice. Japan became a reference point for how to regulate an emerging field without strangling it.
The framework has two distinct parts, and the difference between them is what the Japan story turns on.
The first is the conditional approval pathway for manufacturers: a route to market that requires early evidence of safety and a plausible mechanism, with post-market data collection required to confirm efficacy over time. This produced Japan's conditionally approved regenerative products, including treatments for heart failure and certain eye conditions. Conditional approval is not the same as full approval. The evidence bar is lower by design. But it is a regulatory pathway with oversight, reporting requirements, and the expectation that further data will follow.
The second part of the framework governs what physicians can offer to patients outside that pathway: the uninsured, private-pay market. In Japan, as in many countries, physicians have considerable discretion to offer treatments that have not been formally approved, provided they notify the relevant authorities. This notification requirement was intended to create visibility into what was being offered. In practice, treatments have been provided without adequate verification of safety or efficacy, and the oversight has been insufficient to prevent harm.
The deaths reported in early April occurred in this second category. Patients paying large out-of-pocket sums for regenerative treatments, including beauty-adjacent and cancer-adjacent applications, at private clinics operating within the letter of the law but outside any meaningful evidence standard.
This is not a Japanese problem. The same gap exists wherever physicians have discretion to offer unapproved cell therapies privately. The United States has its own version of it, enforced inconsistently. The difference is that Japan's reporting requirements make it more visible when things go wrong. In other jurisdictions, the deaths and complications simply do not appear in the data at all.
The Japan story reveals the distance between a regulatory framework that exists on paper and one that protects patients in practice. A notification requirement is not the same as a safety review, and a conditional approval is not the same as an evidence standard. A clinic that operates within the law is not, by that fact alone, offering something that works.
STUDY OF THE WEEK
What a properly evidenced MSC therapy looks like
Phase 3 trial — Ryoncil (remestemcel-L), published in Blood, September 2024
Mesoblast's Phase 3 trial enrolled 54 paediatric patients with steroid-refractory acute graft-versus-host disease, a condition with very few treatment options and high mortality. Patients received Ryoncil infusions twice weekly for four weeks.
Study type: Phase 3, single-arm, human patients efficacy compared against historical control data.
Sample size: 54 paediatric patients.
What they found: 70% overall response rate at day 28. 30% complete response, 41% partial response. 180-day survival of 75%, compared to a historical control rate of approximately 45%.
Most important caveat: The trial had no concurrent control group. Comparisons to historical controls carry limitations - patient populations and treatment contexts shift over time. The sample size of 54 is small for a condition with this level of variability.
Why it matters anyway: Ryoncil is the first MSC therapy to clear full FDA approval. It took a specific condition, a rigorous trial design, published data, and years of regulatory dialogue. That is the distance between this and what most clinics are offering under the same two words.
WHAT'S REAL / WHAT'S NOISE / WHAT TO WATCH
REAL
Ryoncil for paediatric steroid-refractory graft-versus-host disease. One approved MSC product, one specific indication, one evidence base that withstood full FDA scrutiny across multiple submissions. If you or someone close to you is dealing with this condition following a bone marrow transplant, this is a real option with a real evidence base. Ask a specialist.
NOISE
Regenerative treatments offered at private clinics in regulatory grey zones, framed as cutting-edge, priced accordingly, and operating with a level of oversight that cannot tell you whether they are safe or whether they work. The Japan story made this visible this month. The same market exists in the United States, South America, Europe, and most other countries with a developed medical tourism infrastructure.
WATCH
Japan's regulatory review, now underway following the deaths and violations reported this month. The Japanese Society for Regenerative Medicine has called for tighter oversight of uninsured treatments. How a country that pioneered conditional approval responds to the consequences of its own framework is a signal worth watching for every country that has followed its lead.
THE RED FLAG REPORT
"Approved in Japan" is not what it sounds like
Some clinics marketing regenerative treatments in other countries cite Japanese approval as a signal of legitimacy. It is worth understanding what that phrase can and cannot mean.
Japan has conditionally approved a small number of regenerative products through its formal regulatory pathway. That pathway requires early safety data and a plausible mechanism, with further evidence expected post-market. It is not the same as full FDA or EMA approval, and the evidence bar is explicitly lower by design.
Japan also has a large private-pay regenerative medicine market operating outside that pathway, subject to notification requirements but not to pre-market efficacy review. Patient deaths have occurred in this second category.
When a clinic says a treatment is approved in Japan, ask which category they mean. If they cannot answer that question precisely, the phrase is doing marketing work, not scientific work.
READER LENS
Conditional approval: what it means and what it does not
This term appears often in regenerative medicine and is regularly misunderstood - sometimes deliberately.
Full approval means a regulatory body has reviewed evidence from at least one large, well-designed clinical trial demonstrating that the treatment works for a specific condition in a specific population, and that the benefits outweigh the risks. The Ryoncil approval is an example.
Conditional approval means the regulator has seen early evidence of safety and a plausible mechanism, and has allowed the treatment onto the market on the condition that the developer continues to collect efficacy data. Japan's conditional approval pathway falls into this category. The treatment is permitted. The evidence is incomplete by design.
When a clinic describes a treatment as conditionally approved, they are describing the second category. It is a regulatory status, not an evidence standard. The word "approved" is doing more work than the evidence behind it.
The clinics operating in Japan's grey zone were not illegal. They filed their notification forms and charged their patients. The oversight framework saw them and did not stop them. Somewhere in that gap are the people who did not survive their treatment.
